Friday, July 2, 2010 - 07:00
Reinach, Switzerland, 2 July 2010 – Evolva Holding SA (SIX: EVE) today announces that Ventureast Trustee Company (P) Limited (“Ventureast”) and APIDC Venture Capital (P) Limited (“APIDC”) have provided CHF 3.5 million of fresh funds to Evolva. This is in line with the commitment that the two investors made in December 2009.
Thursday, June 24, 2010 - 17:54
Evolva Biotech Private Limited (“Evolva India”) is a majority-owned subsidiary of the Evolva group. The unit works on the creation of gene libraries and synthetic and analytical chemistry. In addition, it works on industrial projects and informatics. At the end of 2009, the unit employed 23 people. Evolva India has recently moved from Hyderabad to the Ticel Bio Park in Chennai.
Friday, June 18, 2010 - 17:45
Reinach, Switzerland, 18 June 2010 – Evolva Holding SA (SIX: EVE) today announced that Dr. Jessica Mann will resign as Chief Medical Officer of Evolva as of 31 July 2010 to take up a Senior Development position as Head of Translational Medicine at Hoffman La Roche.
Thursday, June 10, 2010 - 13:15
Reinach, Switzerland, 10 June 2010 – Evolva Holding SA (SIX: EVE) The Annual General Meeting of Evolva Holding SA has approved the proposals that were put forward by the Board of Directors.
Wednesday, June 2, 2010 - 07:00
Reinach, Switzerland, 2 June 2010 – Evolva Holding SA (SIX: EVE) today announced that Dr. Melya Hughes Crameri, CEO of Evolva’s US subsidiary Genetic Chemistry, has resigned from her role effective June 18th, in order to pursue other opportunities. Dr. Panchapagesa Murali, CEO of Evolva’s Indian subsidiary, will serve as acting CEO of Evolva’s US operations until a successor is named.
Thursday, May 20, 2010 - 07:00
Reinach, Switzerland, 20 May 2010 – Evolva Holding SA (SIX: EVE) today announces the agenda items for the Annual General Meeting (AGM) on 10 June 2010. The invitation and agenda items have been published in the official publication organ of the Company and, including the Board of Directors' proposals, sent to registered shareholders.The following items are on the agenda for the meeting.
Tuesday, May 4, 2010 - 07:00
Reinach, Switzerland, 4 May 2010 – Evolva Holding SA (SIX: EVE) is pleased to announce the nomination of Sir Tom McKillop, Claus Braestrup and Nicole Dubois for election to its Board of Directors. The three candidates will be proposed for election in the Annual General Meeting (AGM), to be held on 10 June 2010. Registered shareholders will receive the invitation to the AGM in May.
Monday, April 19, 2010 - 07:00
Reinach, Switzerland, 19 April 2010 – Evolva Holding SA (SIX: EVE) today announced its financial results for the 2009 financial year.
Thursday, March 11, 2010 - 07:00
Reinach, Switzerland, 11th March 2010 – Evolva Holding SA (SIX: EVE) today announced that its Danish subsidiary has commenced a research initiative focusing on novel ways to produce vanillin and arabinogalactan proteins. Together with Evolva, the initiative includes four leading Danish research groups from the University of Copenhagen and the Danish Technical University, Danisco, and the Lawrence Berkeley National Laboratory, a major US research institution.
Monday, January 4, 2010 - 07:00
Basel, Switzerland, 4th January 2010 – Evolva Holding SA (SIX: EVE) today announced that it has signed an agreement with Roche (SIX: ROG, RO; OTCQX: RHHBY) to create compounds with activity on targets in oncology and anti-infectives using Evolva’s technology platform. Roche will pay Evolva an up-front technology access fee and ongoing research fees. Roche will have responsibility to take forward any compounds discovered during the collaboration and will potentially pay Evolva research and clinical milestone fees as well as royalties on any products that result from the collaboration. Evolva will have the first right to any compounds not taken forward, or subsequently deprioritised by Roche.
